CGON

Business Context and Reporting Period

Company: CG Oncology, Inc. (CGON)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: CG Oncology is a late-stage clinical biopharmaceutical company focused on developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer. The company has no approved products and generates revenue primarily from license agreements and, recently, commercial manufacturing services following the acquisition of Biovire, Inc. in July 2025.

Key Financial Metrics

Note: The filing text does not provide specific gross margin percentages as the company is pre-commercialization for its primary product candidate. Cost of sales ($4.6 million) exceeded commercial and development revenue ($3.2 million) in 2025 due to the consolidation of Biovire operations.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $2.9 million (255%) year-over-year, driven by $3.2 million in new commercial and development revenue from the Biovire acquisition. License and collaboration revenue decreased slightly to $0.8 million.
• Expense Increase: Operating expenses rose by $79.0 million. R&D expenses increased by $34.5 million due to higher clinical trial costs and personnel expenses. G&A expenses more than doubled to $73.5 million, reflecting increased headcount, stock-based compensation, and legal fees.
• Net Loss Expansion: Net loss widened by $73.0 million to $161.0 million, primarily due to increased operational costs and the integration of the Biovire acquisition.
• Acquisition: In July 2025, the company acquired a controlling interest in Biovire, Inc., a contract manufacturing organization, for a consideration of approximately $26.8 million. This added $10.3 million in goodwill and $0.6 million in intangible assets to the balance sheet.

Guidance, Outlook, and Risks

Outlook and Management Commentary

• Regulatory Milestone: The company initiated its Biologics License Application (BLA) submission for cretostimogene in the fourth quarter of 2025, based on Phase 3 BOND-003 Cohort C data. Completion is expected in 2026.
• Clinical Progress: Enrollment for the Phase 3 PIVOT-006 trial (intermediate-risk NMIBC) was completed in Q3 2025. Topline data is expected in the first half of 2026.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($742.2 million as of Dec 31, 2025) are sufficient to fund operations for at least the next 12 months.
• Capital Raising: The company utilized an At-The-Market (ATM) facility with Jefferies LLC, raising $147.1 million in 2025 and an additional $188.0 million in the subsequent period (Jan-Feb 2026).

Risks and Contingencies

• Single Product Dependence: The company's success depends entirely on cretostimogene. Failure to obtain FDA approval or commercialize the product would materially harm the business.
• Regulatory Uncertainty: While the company has Fast Track and Breakthrough Therapy designations, the FDA may require additional data or issue a Complete Response Letter (CRL).
• Manufacturing Reliance: Despite acquiring Biovire, the company relies on third parties for certain manufacturing steps and raw materials. Supply chain disruptions could delay trials or commercialization.
• Legal Proceedings: The company successfully defended against a lawsuit by ANI Pharmaceuticals regarding royalty obligations in July 2025, but ANI may pursue appeals.

Key Facts for Investor Verification

• BLA Submission Status: Verify the exact filing date and FDA acceptance status of the BLA for cretostimogene in high-risk BCG-unresponsive NMIBC.
• Cash Runway: Confirm the current cash burn rate and whether the $742.2 million cash balance (plus subsequent ATM proceeds) remains sufficient to fund operations through 2027 without further dilution.
• Biovire Integration: Assess the financial performance of Biovire post-acquisition and its ability to meet commercial supply demands if cretostimogene is approved.
• Clinical Data Readouts: Monitor the timing and results of the PIVOT-006 topline data readout expected in H1 2026.
• ATM Facility Usage: Track the remaining capacity under the Jefferies Sales Agreement ($550 million aggregate offering price) and the pace of share sales.